AstraZeneca Allemansfond

Legal name: AstraZeneca Allemansfond
Equity Fund Registered in Sweden (Non-UCITS) Bid

About risk

Historical yields are not a guarantee of future returns. A fund can both increase and decrease in value and it is not guaranteed that you will recover the entire invested amount. Note that a fund with risk level 5-7, as stated in the fund's fact sheet (KID), can vary greatly in value due to the fund's composition and management methodology. The prospectus, fund rules and KID are available under each fund. Summary of investors' rights.

Fact sheet and documents Print page
Factsheet and Information Brochure
Factsheet 
Target Market
Costs and charges
Fund rules (136 kB)
Prospectus (1369 kB)
Periodic reports
Sustainability SFDR (924 kB)
Annual review (PF) (2879 kB)
Semi-annual report (1799 kB)
Marketing material
Brief fund information 
Summary SFDR (143 kB)
The fund is actively managed special fund (non-UCITS) and thereby the fund deviates from a UCITS fund by concentrating holdings to a smaller number of equities issued by companies in primarily Sweden. The fund invests a significant amount (maximum of 50% of assets) in AstraZeneca.

The fund is reported as an Article 8 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).
Ulrika Orstadius

Fund manager

Ulrika Orstadius Experience in the fund industry 2011. Portfolio Manager since 1 November 2022.
Risk: 4/7
Risk  4/7
 
The risk indicator provides guidance on the risk level for this product relative to other financial products. It shows the likelihood that the product will decrease in value due to market performance. Risk level 1 represents a low risk and risk level 7 is a high risk.
Rating: 5
Total Rating™ 
30.04.2024
The rating shows which funds have historically posted the strongest performance in relation to risk. Ratings are denoted by a scale of one to five stars, with five as the highest rating. A fund must have a performance history of at least three years to receive a rating.
Read more about the fund's rating
EuapIndicator:1
SFDR
 
This fund promotes environmental and social characteristics through its investments but does not have sustainable investments as its objective. As a result, the fund takes into consideration the environment and climate, as well as human rights, employees’ rights and corruption.
The fund is reported as an Article 8 fund pursuant to EU regulation on sustainability-related disclosures in the financial services sector (SFDR).
  29.02.2024
Sustainability-
rating

The sustainability rating is developed by the fund information company Morningstar. The rating measures how well the fund's investee companies manage sustainability risks relative to other funds within the same global Morningstar category. If the fund has invested in government bonds issued by sovereign states, the respective country's sustainability risk is included in the calculation. The analyzed funds can receive a sustainability rating between 1 and 5 globes, with 5 as the highest rating.

The fund complies with the UN Principles for Responsible Investments.

Graph

In percent including distribution in SEK
Compare funds
AstraZeneca Allemansfond (SEK)

Note that benchmark returns, unlike fund returns, do not take distributions into account. As a result, fund returns are higher than they would otherwise be relative to benchmark.

Performance

Rate 08.05.2024 1 week 1 month 3 months 2024 1 year 5 years 10 years
4,129.69 SEK 1.33% 8.57% 18.93% 17.16% 16.72% 124.74% 304.26%

Portfolio 26.04.2024

Fund performance was favorable during Q1 2024 and the fund rose just over 9% in SEK. The upturns in the equity market were primarily driven by an increased confidence in a soft landing of the economy that is supported by expected rate cuts.

The strongest contributors to fund returns were Astra Zeneca, Volvo and SEB, where Astra Zeneca rebounded after declining on the reporting date in the wake of higher than expected costs. Volvo posted strength in line with the rest of the manufacturing sector and SEB announced a share buyback program in conjunction with its quarterly report, which was received positively by the market.

Nibe and Sweco, which were weighed down by reports that were weaker than expected, had the most negative impact on returns. Nibe’s sales were negatively affected by the persistently high inventories of heating pumps in the distribution chain that were accumulated during a period of high expectations for further strong growth and the need to ensure delivery capacity. Declining gas prices in Europe and lower subsidies have dampened incentives for installing heating pumps. The inventory situation should be rebalanced during the end of the year and there is a further need for energy transition that is assisted by effective climate solutions over the long term. Sweco was weighed down by struggles in the UK market where projects within transport are being cancelled and the company is now adjusting after the overcapacity that arose.

The fund increased the holdings in Nolato, Astra Zeneca and Nibe during the quarter as well as took profits in Indutrade after strong stock performance. We decreased the holdings in SHB, Volvo and Atlas Copco during the quarter.

In the upcoming reporting period we will continue to focus on investee companies that have sustainable business models and competitive offers with sustainable growth even in a weaker economy.

Portfolio distribution 30.04.2024

Geographic breakdown 30.04.2024

world_map